VerbatimParliament, as it happens

Prostate Cancer: Abiraterone

Asked by Sorcha EastwoodAllianceDepartment of Health and Social CareTabled Answered 28 January 2026UIN 107546

The question

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of Northern Ireland being the only part of the UK without routine access to abiraterone for men with non-metastatic prostate cancer on patient outcomes across the UK.

Answered by Dr Zubir Ahmed

There are no current plans to hold discussions with the Northern Irish Department of Health or the Health and Social Care Board on abiraterone access in Northern Ireland. Decisions on the availability of medicines in Northern Ireland are a matter for the Northern Ireland Executive.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim